Sei Investments Co. Grows Position in Kura Oncology, Inc. $KURA

Sei Investments Co. boosted its position in Kura Oncology, Inc. (NASDAQ:KURA) by 74.0% during the 1st quarter, Holdings Channel reports. The fund owned 319,266 shares of the company’s stock after acquiring an additional 135,818 shares during the quarter. Sei Investments Co.’s holdings in Kura Oncology were worth $2,596,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Kura Oncology by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after purchasing an additional 2,977 shares during the last quarter. Strs Ohio acquired a new position in shares of Kura Oncology during the first quarter worth $143,000. Legal & General Group Plc increased its holdings in Kura Oncology by 35.1% in the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after buying an additional 18,930 shares during the last quarter. Rhumbline Advisers increased its holdings in Kura Oncology by 13.0% in the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after buying an additional 13,690 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Kura Oncology by 244.5% in the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after buying an additional 165,189 shares in the last quarter.

Insider Buying and Selling at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider directly owned 182,345 shares in the company, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 7.60% of the company’s stock.

Analyst Ratings Changes

KURA has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research report on Thursday, June 4th. CLSA set a $24.00 target price on Kura Oncology in a research note on Thursday, June 4th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a report on Monday, June 15th. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Tuesday, July 28th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.46.

Kura Oncology Price Performance

Shares of KURA opened at $9.57 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. Kura Oncology, Inc. has a 1-year low of $5.45 and a 1-year high of $12.49. The stock has a market cap of $849.53 million, a PE ratio of -2.86 and a beta of 0.38. The firm has a fifty day moving average price of $10.09 and a 200 day moving average price of $9.28.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The company had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. As a group, sell-side analysts anticipate that Kura Oncology, Inc. will post -3.45 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.